Funding Received
$9.8 Million in 3 Rounds from 2 Investors
Most Recent Funding
$3 Million Venture on December, 2007
Headquarters:
Montréal, QC
Description:
AngioChem develops new drugs that are capable of crossing the blood-brain barrier to treat brain diseases.
Categories:
Biotechnology
Website:
http://www.angiochem.com

Company Details

Update

AngioChem is a clinical-stage biotechnology discovering and developing new breakthrough drugs that are uniquely capable of crossing the blood-brain barrier to treat brain diseases. Their EPiC platform solves the key problem for crossing the blood-brain barrier by developing novel drugs that use a receptor-based approach. These novel Engineered Peptide Compounds (EPiC) have the potential to address significant medical needs, many of which cannot be effectively addressed due to the fundamental physiological challenge the blood-brain barrier presents for therapeutic intervention.

Funding Rounds (3) - $9.8M

Update

Board Members and Advisors (1)

Update

Investors (2)

Update
  • Cb default image 58x58

    VIMAC Milestone Medical Fund

    The VIMAC Milestone Medica Fund (VMM) is a life sciences venture capital fund providing equity...
  • Bf2333d0da2fdd635613e46f9ebcad9b

    BDC Venture Capital

    BDC Venture Capital is a major venture capital investor in Canada, active at every stage of the...

Offices/Locations (1)

Update
  • Office

    201 President-Kennedy Ave

    Suite PK-R220, Quebec,

    Montréal, QC H2X 3Y7

    CAN

Images (1)

Update
  • 33fc753ab5289aedd8f5dad267276e0c